Table of Contents
New Journal of Science
Volume 2014, Article ID 390618, 27 pages
http://dx.doi.org/10.1155/2014/390618
Review Article

Endocrine Resistance in Breast Cancer

Edinburgh Breakthrough Breast Cancer Research Group, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, Scotland

Received 27 April 2014; Accepted 23 July 2014; Published 17 September 2014

Academic Editor: Heidi Fiegl

Copyright © 2014 J. M. Dixon. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. R. D. Johnston and M. Dowsett, “Aromatase inhibitors for breast cancer: lessons from the laboratory,” Nature Reviews Cancer, vol. 3, no. 11, pp. 821–831, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. A. A. Larionov and W. R. Miller, “Challenges in defining predictive markers for response to endocrine therapy in breast cancer,” Future Oncology, vol. 5, no. 9, pp. 1415–1428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Smuk and J. Schwers, “Aromatization of androstenedione by human adult liver in vitro,” Journal of Clinical Endocrinology and Metabolism, vol. 45, no. 5, pp. 1009–1012, 1977. View at Publisher · View at Google Scholar · View at Scopus
  4. E. R. Simpson and M. Dowsett, “Aromatase and its inhibitors: significance for breast cancer therapy,” Recent Progress in Hormone Research, vol. 57, pp. 317–338, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. A. A. Larionov, D. A. Vasyliev, J. I. Mason, A. F. Howie, L. M. Berstein, and W. R. Miller, “Aromatase in skeletal muscle,” Journal of Steroid Biochemistry and Molecular Biology, vol. 84, no. 4, pp. 485–492, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Perel and D. W. Killinger, “The interconversion and aromatization of androgens by human adipose tissue,” Journal of Steroid Biochemistry, vol. 10, no. 6, pp. 623–627, 1979. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Longcope, J. H. Pratt, S. H. Schneider, and S. E. Fineberg, “Aromatization of androgens by muscle and adipose tissue in vivo,” Journal of Clinical Endocrinology and Metabolism, vol. 46, no. 1, pp. 146–152, 1978. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Sasano, M. Uzuki, T. Sawai et al., “Aromatase in human bone tissue,” Journal of Bone and Mineral Research, vol. 12, no. 9, pp. 1416–1423, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. W. R. Miller and A. P. M. Forrest, “Oestradiol synthesis by a human breast carcinoma,” The Lancet, vol. 2, no. 7885, pp. 866–868, 1974. View at Google Scholar · View at Scopus
  10. J. R. Pasqualini, G. Chetrite, C. Blacker et al., “Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 4, pp. 1460–1464, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. T. J. Key, “Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies,” Journal of the National Cancer Institute, vol. 94, no. 8, pp. 606–616, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. W. R. Miller and J. O'Neill, “The importance of local synthesis of estrogen within the breast,” Steroids, vol. 50, no. 4–6, pp. 537–548, 1987. View at Publisher · View at Google Scholar · View at Scopus
  13. S. E. Bulun, G. Sharda, J. Rink, S. Sharma, and E. R. Simpson, “Distribution of aromatase p450 transcripts and adipose fibroblasts in the human breast,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 3, pp. 1273–1277, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Harada, T. Utsumi, and Y. Takagi, “Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 23, pp. 11312–11316, 1993. View at Google Scholar · View at Scopus
  15. M. P. Schrey and K. V. Patel, “Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators,” British Journal of Cancer, vol. 72, no. 6, pp. 1412–1419, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. K. B. Horwitz, T. A. Jackson, D. L. Bain, J. K. Richer, G. S. Takimoto, and L. Tung, “Nuclear receptor coactivators and corepressors,” Molecular Endocrinology, vol. 10, no. 10, pp. 1167–1177, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Kumar, S. Green, G. Stack, M. Berry, J. Jin, and P. Chambon, “Functional domains of the human estrogen receptor,” Cell, vol. 51, no. 6, pp. 941–951, 1987. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Beato, “Gene regulation by steroid hormones,” Cell, vol. 56, no. 3, pp. 335–344, 1989. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Tsai and B. W. O'Malley, “Molecular mechanisms of action of steroid/thyroid receptor superfamily members,” Annual Review of Biochemistry, vol. 63, pp. 451–486, 1994. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Kato, H. Endoh, Y. Masuhiro et al., “Activation of the estrogen receptor through phosphorylation by mitoqen-activated protein kinase,” Science, vol. 270, no. 5241, pp. 1491–1494, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. A. E. Wakeling, “Similarities and distinctions in the mode of action of different classes of antioestrogens,” Endocrine-Related Cancer, vol. 7, no. 1, pp. 17–28, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Reid, M. R. Hübner, R. Métivier et al., “Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling,” Molecular Cell, vol. 11, no. 3, pp. 695–707, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Bourdeau, J. Deschênes, R. Métivier et al., “Genome-wide identification of high-affinity estrogen response elements in human and mouse,” Molecular Endocrinology, vol. 18, no. 6, pp. 1411–1427, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Klein-Hitpass, G. U. Ryffel, E. Heitlinger, and A. C. B. Cato, “A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor,” Nucleic Acids Research, vol. 16, no. 2, pp. 647–663, 1988. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kamalakaran, S. K. Radhakrishnan, and W. T. Beck, “Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites,” The Journal of Biological Chemistry, vol. 280, no. 22, pp. 21491–21497, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. C. J. Gruber, D. M. Gruber, I. M. L. Gruber, F. Wieser, and J. C. Huber, “Anatomy of the estrogen response element,” Trends in Endocrinology & Metabolism, vol. 15, no. 2, pp. 73–78, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Scholz, M. Truss, and M. Beato, “Hormone-induced recruitment of Sp1 mediates estrogen activation of the rabbit uteroglobin gene in endometrial epithelium,” The Journal of Biological Chemistry, vol. 273, no. 8, pp. 4360–4366, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. C. M. Klinge, “Estrogen receptor interaction with estrogen response elements,” Nucleic Acids Research, vol. 29, no. 14, pp. 2905–2919, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Brown and P. A. Sharp, “Human estrogen receptor forms multiple protein-DNA complexes,” Journal of Biological Chemistry, vol. 265, no. 19, pp. 11238–11243, 1990. View at Google Scholar · View at Scopus
  30. J. A. Lees, S. E. Fawell, and M. G. Parker, “Identification of two transactivation domains in the mouse oestrogen receptor,” Nucleic Acids Research, vol. 17, no. 14, pp. 5477–5488, 1989. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Kumar and P. Chambon, “The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer,” Cell, vol. 55, no. 1, pp. 145–156, 1988. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Caizzi, G. Ferrero, S. Cutrupi et al., “Genome-wide activity of unliganded estrogen receptor-alpha in breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 13, pp. 4892–4897, 2014. View at Publisher · View at Google Scholar
  33. E. A. Musgrove and R. L. Sutherland, “Biological determinants of endocrine resistance in breast cancer,” Nature Reviews Cancer, vol. 9, no. 9, pp. 631–643, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. R. B. Clarke, A. Howell, C. S. Potten, and E. Anderson, “Dissociation between steroid receptor expression and cell proliferation in the human breast,” Cancer Research, vol. 57, no. 22, pp. 4987–4991, 1997. View at Google Scholar · View at Scopus
  35. O. W. J. Prall, B. Sarcevic, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland, “Estrogen-induced activation of Cdk4 and Cdk2 during G 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2,” Journal of Biological Chemistry, vol. 272, no. 16, pp. 10882–10894, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. J. S. Foster, D. C. Henley, A. Bukovsky, P. Seth, and J. Wimalasena, “Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function,” Molecular and Cellular Biology, vol. 21, no. 3, pp. 794–810, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Sabbah, D. Courilleau, J. Mester, and G. Redeuilh, “Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11217–11222, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. M. M. Liu, C. Albanese, C. M. Anderson et al., “Opposing action of estrogen receptors α and β on cyclin D1 gene expression,” The ournal of Biological Chemistry, vol. 277, no. 27, pp. 24353–24360, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Cicatiello, R. Addeo, A. Sasso et al., “Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter,” Molecular and Cellular Biology, vol. 24, no. 16, pp. 7260–7274, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Safe, “Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions,” Vitamins and Hormones, vol. 62, pp. 231–252, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Webb, G. N. Lopez, R. M. Uht, and P. J. Kushner, “Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens,” Molecular Endocrinology, vol. 9, no. 4, pp. 443–456, 1995. View at Google Scholar · View at Scopus
  42. E. Neuman, M. H. Ladha, N. Lin et al., “Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4,” Molecular and Cellular Biology, vol. 17, no. 9, pp. 5338–5347, 1997. View at Google Scholar · View at Scopus
  43. M. Meyerson and E. Harlow, “Identification of G1 kinase activity for cdk6, a novel cyclin D partner,” Molecular and Cellular Biology, vol. 14, no. 3, pp. 2077–2086, 1994. View at Google Scholar · View at Scopus
  44. C. E. Caldon, R. J. Daly, R. L. Sutherland, and E. A. Musgrove, “Cell cycle control in breast cancer cells,” Journal of Cellular Biochemistry, vol. 97, no. 2, pp. 261–274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Dubik and R. P. C. Shiu, “Mechanism of estrogen activation of c-myc oncogene expression,” Oncogene, vol. 7, no. 8, pp. 1587–1594, 1992. View at Google Scholar · View at Scopus
  46. K. Galaktionov, X. Chen, and D. Beach, “Cdc25 cell-cycle phosphatase as a target of c-myc,” Nature, vol. 382, no. 6591, pp. 511–517, 1996. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Hermeking, C. Rago, M. Schuhmacher et al., “Identification of CDK4 as a target of c-MYC,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 5, pp. 2229–2234, 2000. View at Google Scholar
  48. S. Lacy and P. Whyte, “Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes,” Oncogene, vol. 14, no. 20, pp. 2395–2406, 1997. View at Publisher · View at Google Scholar · View at Scopus
  49. O. W. J. Prall, E. M. Rogan, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland, “c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry,” Molecular and Cellular Biology, vol. 18, no. 8, pp. 4499–4508, 1998. View at Google Scholar · View at Scopus
  50. M. D. Planas-Silva and R. A. Weinberg, “Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution,” Molecular and Cellular Biology, vol. 17, no. 7, pp. 4059–4069, 1997. View at Google Scholar · View at Scopus
  51. J. S. Foster, R. I. Fernando, N. Ishida, K. I. Nakayama, and J. Wimalasena, “Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway,” Journal of Biological Chemistry, vol. 278, no. 42, pp. 41355–41366, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Castoria, A. Migliaccio, M. di Domenico et al., “Role of atypical protein kinase C in estradiol-triggered G1/S progression of MCF-7 cells,” Molecular and Cellular Biology, vol. 24, no. 17, pp. 7643–7653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Haddow, J. M. Watkinson, E. Paterson, and P. C. Koller, “Influence of synthetic oestrogens on advanced malignant disease,” British Medical Journal, vol. 2, no. 4368, pp. 393–398, 1944. View at Google Scholar
  54. V. C. Jordan, “Tamoxifen: a most unlikely pioneering medicine,” Nature Reviews Drug Discovery, vol. 2, no. 3, pp. 205–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Schick, J. Goodstein, J. Moor, J. Butler, and K. L. Senter, “Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer,” Journal of Surgical Oncology, vol. 22, no. 4, pp. 278–282, 1983. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Kaufmann, G. N. Hortobagyi, and A. Goldhirsch, “Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update,” Journal of Clinical Oncology, vol. 24, no. 19, p. 3221, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. V. F. Semiglazov, V. V. Semiglazov, G. A. Dashyan et al., “Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer,” Cancer, vol. 110, no. 2, pp. 244–254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Perloff and C. J. Lesnick, “Chemotherapy before and after mastectomy in stage III breast cancer,” Archives of Surgery, vol. 117, no. 7, pp. 879–881, 1982. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Colleoni, S. Gelber, A. S. Coates et al., “Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer,” Journal of Clinical Oncology, vol. 19, no. 21, pp. 4141–4149, 2001. View at Google Scholar · View at Scopus
  60. L. Gianni, J. Baselga, W. Eiermann et al., “Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy,” Clinical Cancer Research, vol. 11, no. 24, part 1, pp. 8715–8721, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Dowsett, I. E. Smith, S. R. Ebbs et al., “Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer,” Clinical Cancer Research, vol. 12, no. 3, part 2, pp. 1024s–1030s, 2006. View at Google Scholar
  62. S. F. Doisneau-Sixou, C. M. Sergio, J. S. Carroll, R. Hui, E. A. Musgrove, and R. L. Sutherland, “Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells,” Endocrine-Related Cancer, vol. 10, no. 2, pp. 179–186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. A. K. Shiau, D. Barstad, P. M. Loria et al., “The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen,” Cell, vol. 95, no. 7, pp. 927–937, 1998. View at Publisher · View at Google Scholar · View at Scopus
  64. C. M. Klinge, S. C. Jernigan, S. L. Smith, V. V. Tyulmenkov, and P. C. Kulakosky, “Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor α,” Molecular and Cellular Endocrinology, vol. 174, no. 1-2, pp. 151–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. X. Long and K. P. Nephew, “Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α,” Journal of Biological Chemistry, vol. 281, no. 14, pp. 9607–9615, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Howell, J. F. R. Robertson, P. Abram et al., “Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1605–1613, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. A. U. Buzdar, “Fulvestrant—a novel estrogen receptor antagonist for the treatment of advanced breast cancer,” Drugs of Today, vol. 44, no. 9, pp. 679–692, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. P. E. Goss, J. N. Ingle, S. Martino et al., “A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer,” The New England Journal of Medicine, vol. 349, no. 19, pp. 1793–1802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. A. U. Buzdar, “Aromatase inhibitors: changing the face of endocrine therapy for breast cancer,” Breast Disease, vol. 24, no. 1, pp. 107–117, 2005. View at Google Scholar · View at Scopus
  70. Y. Kao, L. L. Cam, C. A. Laughton, D. Zhou, and S. Chen, “Binding characteristics of seven inhibitors of human aromatase: a site- directed mutagenesis study,” Cancer Research, vol. 56, no. 15, pp. 3451–3460, 1996. View at Google Scholar · View at Scopus
  71. R. Carpenter and W. R. Miller, “Role of aromatase inhibitors in breast cancer,” British Journal of Cancer, vol. 93, supplement 1, pp. S1–S5, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. R. C. Coombes, E. Hall, L. J. Gibson et al., “A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer,” The New England Journal of Medicine, vol. 350, no. 11, pp. 1081–1092, 2004. View at Publisher · View at Google Scholar
  73. I. E. Smith and M. Dowsett, “Aromatase inhibitors in breast cancer,” The New England Journal of Medicine, vol. 348, no. 24, pp. 2431–2442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. W. R. Miller, A. Larionov, L. Renshaw et al., “Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1382–1387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Howell and M. Dowsett, “Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens,” Breast Cancer Research, vol. 6, no. 6, pp. 269–274, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. W. R. Miller and J. Jackson, “The therapeutic potential of aromatase inhibitors,” Expert Opinion on Investigational Drugs, vol. 12, no. 3, pp. 337–351, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. Early Breast Cancer Trialists' Collaborative Group, “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005. View at Google Scholar
  78. A. Brodie, L. MacEdo, and G. Sabnis, “Aromatase resistance mechanisms in model systems in vivo,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 118, no. 4-5, pp. 283–287, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. M. J. Ellis, V. J. Suman, J. Hoog et al., “Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031,” Journal of Clinical Oncology, vol. 29, no. 17, pp. 2342–2349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Bartsch, Z. Bago-Horvath, A. Berghoff et al., “Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer,” European Journal of Cancer, vol. 48, no. 13, pp. 1932–1938, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. J. C. Doughty, “When to start an aromatase inhibitor: now or later?” Journal of Surgical Oncology, vol. 103, no. 7, pp. 730–738, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. I. E. Smith, M. Dowsett, S. R. Ebbs et al., “Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 5108–5116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Mustacchi, M. Mansutti, C. Sacco et al., “Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study,” Annals of Oncology, vol. 20, no. 4, pp. 655–659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. M. J. Ellis, Y. Tao, O. Young et al., “Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3019–3025, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Burcombe, G. D. Wilson, M. Dowsett et al., “Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer,” Breast Cancer Research, vol. 8, no. 3, article R31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. V. Guarneri and P. F. Conte, “The curability of breast cancer and the treatment of advanced disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, supplement 1, pp. S149–S161, 2004. View at Google Scholar · View at Scopus
  87. A. M. Gonzalez-Angulo, F. Morales-Vasquez, and G. N. Hortobagyi, “Overview of resistance to systemic therapy in patients with breast cancer,” Advances in Experimental Medicine and Biology, vol. 608, pp. 1–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Dowsett, J. Cuzick, J. Ingle et al., “Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen,” Journal of Clinical Oncology, vol. 28, no. 3, pp. 509–518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. C. X. Ma, C. G. Sanchez, and M. J. Ellis, “Predicting endocrine therapy responsiveness in breast cancer,” Oncology, vol. 23, no. 2, pp. 133–142, 2009. View at Google Scholar · View at Scopus
  90. M. Colleoni and E. Montagna, “Neoadjuvant therapy for ER-positive breast cancers,” Annals of Oncology, vol. 23, supplement 10, pp. x243–x248, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Takatsuka, E. Yayoi, H. Inaji, and T. Aikawa, “A comparison of two doses of tamoxifen in patients with advanced breast cancer: 20 mg/day versus 40 mg/day,” Gan To Kagaku Ryoho, vol. 16, no. 5, pp. 2093–2097, 1989 (Japanese). View at Google Scholar
  92. A. Ring and M. Dowsett, “Mechanisms of tamoxifen resistance,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 643–658, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. S. P. Hasson, T. Rubinek, L. Ryvo, and I. Wolf, “Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling pathway,” Breast Care, vol. 8, no. 4, pp. 248–255, 2013. View at Google Scholar
  94. X. Sun, D. Zhou, and S. Chen, “Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells,” Journal of Steroid Biochemistry and Molecular Biology, vol. 63, no. 1–3, pp. 29–36, 1997. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Masri, S. Phung, X. Wang et al., “Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor,” Cancer Research, vol. 68, no. 12, pp. 4910–4918, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. K. J. Taylor, A. H. Sims, L. Liang et al., “Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer,” Breast Cancer Research, vol. 12, no. 3, article R39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. W. R. Miller, A. A. Larionov, L. Renshaw et al., “Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole,” Pharmacogenetics and Genomics, vol. 17, no. 10, pp. 813–826, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. W. R. Miller, A. Larionov, L. Renshaw et al., “Aromatase inhibitors—gene discovery,” Journal of Steroid Biochemistry and Molecular Biology, vol. 106, no. 1–5, pp. 130–142, 2007. View at Google Scholar
  99. R. L. Sutherland and E. A. Musgrove, “Cyclins and breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 9, no. 1, pp. 95–104, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. R. B. Riggins, A. H. Bouton, M. C. Liu, and R. Clarke, “Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer,” Vitamins and Hormones, vol. 71, pp. 201–237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Mandlekar and A.-N. T. Kong, “Mechanisms of tamoxifen-induced apoptosis,” Apoptosis, vol. 6, no. 6, pp. 469–477, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Ishii, S. Waxman, and D. Germain, “Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3,” Cancer Research, vol. 68, no. 3, pp. 852–860, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Akli, T. Bui, H. Wingate et al., “Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors,” Clinical Cancer Research, vol. 16, no. 4, pp. 1179–1190, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. C. E. Caldon, C. M. Sergio, J. Kang et al., “Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells,” Molecular Cancer Therapeutics, vol. 11, no. 7, pp. 1488–1499, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Venditti, B. Iwasiow, F. W. Orr, and R. P. C. Shiu, “C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells,” International Journal of Cancer, vol. 99, no. 1, pp. 35–42, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Cariou, J. C. H. Donovan, W. M. Flanagan, A. Milic, N. Bhattacharya, and J. M. Slingerland, “Down-regulation of p21WAF1/CIP1 or p27KiP1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 9042–9046, 2000. View at Google Scholar · View at Scopus
  107. S. Sengupta, M. C. Biarnes, and V. C. Jordan, “Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers,” Breast Cancer Research and Treatment, vol. 143, no. 1, pp. 113–124, 2014. View at Publisher · View at Google Scholar
  108. N. Harbeck and A. Rody, “Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer,” Journal of Clinical Oncology, vol. 30, no. 7, pp. 686–689, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. T. Iwamoto, D. Booser, V. Valero et al., “Estrogen Receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry,” Journal of Clinical Oncology, vol. 30, no. 7, pp. 729–734, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. L. K. Dunnwald, M. A. Rossing, and C. I. Li, “Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients,” Breast Cancer Research, vol. 9, no. 1, article R6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Carracedo, M. Salido, J. M. Corominas et al., “Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study,” Cancer Genetics, vol. 205, no. 4, pp. 138–146, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. M. C. Diaz Flaque, N. M. Galigniana, W. Béguelin et al., “Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy,” Breast Cancer Research, vol. 15, no. 6, p. R118, 2013. View at Publisher · View at Google Scholar
  113. A. E. Gururaj, S. K. Rayala, R. K. Vadlamudi et al., “Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations,” Clinical Cancer Research, vol. 12, part 2, no. 3, pp. 1001s–1007s, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. V. C. Jordan, “Selective estrogen receptor modulation: concept and consequences in cancer,” Cancer Cell, vol. 5, no. 3, pp. 207–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. J. M. Knowlden, I. R. Hutcheson, H. E. Jones et al., “Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells,” Endocrinology, vol. 144, no. 3, pp. 1032–1044, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. R. A. McClelland, D. Barrow, T. Madden et al., “Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex),” Endocrinology, vol. 142, no. 7, pp. 2776–2788, 2001. View at Publisher · View at Google Scholar · View at Scopus
  117. C. S. Ross-Innes, R. Stark, A. E. Teschendorff et al., “Differential oestrogen receptor binding is associated with clinical outcome in breast cancer,” Nature, vol. 481, no. 7381, pp. 389–393, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. J. S. Carroll, X. S. Liu, A. S. Brodsky et al., “Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1,” Cell, vol. 122, no. 1, pp. 33–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Lupien, J. Eeckhoute, C. A. Meyer et al., “FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription,” Cell, vol. 132, no. 6, pp. 958–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Hurtado, K. A. Holmes, C. S. Ross-Innes, D. Schmidt, and J. S. Carroll, “FOXA1 is a key determinant of estrogen receptor function and endocrine response,” Nature Genetics, vol. 43, no. 1, pp. 27–33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. K. Merenbakh-Lamin, N. Ben-Baruch, A. Yeheskel et al., “D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer,” Cancer Research, vol. 73, no. 23, pp. 6856–6864, 2013. View at Google Scholar
  122. D. R. Robinson, Y. M. Wu, P. Vats et al., “Activating ESR1 mutations in hormone-resistant metastatic breast cancer,” Nature Genetics, vol. 45, no. 12, pp. 1446–1451, 2013. View at Publisher · View at Google Scholar
  123. R. Jeselsohn, R. Yelensky, G. Buchwalter et al., “Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer,” Clinical Cancer Research, vol. 20, no. 7, pp. 1757–1767, 2014. View at Publisher · View at Google Scholar
  124. I. Barone, L. Brusco, and S. A. W. Fuqua, “Estrogen receptor mutations and changes in downstream gene expression and signaling,” Clinical Cancer Research, vol. 16, no. 10, pp. 2702–2708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. S. R. D. Johnston, G. Saccani-Jotti, I. E. Smith et al., “Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer,” Cancer Research, vol. 55, no. 15, pp. 3331–3338, 1995. View at Google Scholar · View at Scopus
  126. M. C. Gutierrez, S. Detre, S. Johnston et al., “Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase,” Journal of Clinical Oncology, vol. 23, no. 11, pp. 2469–2476, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. R. Clarke, H. W. Ressom, A. Wang et al., “The properties of high-dimensional data spaces: implications for exploring gene and protein expression data,” Nature Reviews Cancer, vol. 8, no. 1, pp. 37–49, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. M. H. Herynk and S. A. W. Fuqua, “Estrogen receptor mutations in human disease,” Endocrine Reviews, vol. 25, no. 6, pp. 869–898, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. R. B. Riggins, R. S. Schrecengost, M. S. Guerrero, and A. H. Bouton, “Pathways to tamoxifen resistance,” Cancer Letters, vol. 256, no. 1, pp. 1–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. G. Li, J. Zhang, K. Jin et al., “Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells,” Molecular Oncology, vol. 7, no. 3, pp. 611–624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. M. M. Heckler, H. Thakor, C. C. Schafer, and R. B. Riggins, “ERK/MAPK regulates ERRgamma expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer,” FEBS Journal, vol. 281, no. 10, pp. 2431–2442, 2014. View at Google Scholar
  132. D. Wang, P. Huang, B. Zhu, L. Sun, Q. Huang, and J. Wang, “Induction of estrogen receptor α-36 expression by bone morphogenetic protein 2 in breast cancer cell lines,” Molecular Medicine Reports, vol. 6, no. 3, pp. 591–596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. L. Shi, B. Dong, Z. Li et al., “Expression of ER-α 36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3423–3429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. R. B. Riggins, J. P.-J. Lan, U. Klimach et al., “ERRγ mediates tamoxifen resistance in novel models of invasive lobular breast cancer,” Cancer Research, vol. 68, no. 21, pp. 8908–8917, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. K. Paech, P. Webb, G. G. J. M. Kuiper et al., “Differential ligand activation of estrogen receptors ERα and ERrβ at AP1 sites,” Science, vol. 277, no. 5331, pp. 1508–1510, 1997. View at Publisher · View at Google Scholar · View at Scopus
  136. P. J. Kushner, D. A. Agard, G. L. Greene et al., “Estrogen receptor pathways to AP-1,” Journal of Steroid Biochemistry and Molecular Biology, vol. 74, no. 5, pp. 311–317, 2000. View at Google Scholar
  137. V. Speirs, C. Malone, D. S. Walton, M. J. Kerin, and S. L. Atkin, “Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients,” Cancer Research, vol. 59, no. 21, pp. 5421–5424, 1999. View at Google Scholar · View at Scopus
  138. M. Madeira, A. Mattar, A. F. Logullo, F. A. Soares, and L. H. Gebrim, “Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness—a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer,” BMC Cancer, vol. 13, article 425, 2013. View at Publisher · View at Google Scholar
  139. M. Lupien, C. A. Meyer, S. T. Bailey et al., “Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance,” Genes and Development, vol. 24, no. 19, pp. 2219–2227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. J. R. C. Sainsbury, J. R. Farndon, G. V. Sherbet, and A. L. Harris, “Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer,” The Lancet, vol. 1, no. 8425, pp. 364–366, 1985. View at Google Scholar · View at Scopus
  141. M. Koga, E. A. Musgrove, and R. L. Sutherland, “Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin,” Cancer Research, vol. 49, no. 1, pp. 112–116, 1989. View at Google Scholar · View at Scopus
  142. R. X.-D. Song, Y. Chen, Z. Zhang et al., “Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells,” Journal of Steroid Biochemistry and Molecular Biology, vol. 118, no. 4-5, pp. 219–230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. J. Shou, S. Massarweh, C. K. Osborne et al., “Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer,” Journal of the National Cancer Institute, vol. 96, no. 12, pp. 926–935, 2004. View at Publisher · View at Google Scholar · View at Scopus
  144. Z. Mo, M. Liu, F. Yang et al., “GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer,” Breast Cancer Research, vol. 15, no. 6, article R114, 2013. View at Publisher · View at Google Scholar
  145. O. Pontiggia, R. Sampayo, D. Raffo et al., “The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin,” Breast Cancer Research and Treatment, vol. 133, no. 2, pp. 459–471, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Rieber and M. Strasberg-Rieber, “p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα + breast cancer MCF-7 cells,” Biochemical Pharmacology, vol. 88, no. 2, pp. 169–177, 2014. View at Google Scholar
  147. K. Lindberg, L. A. Helguero, Y. Omoto, J. Gustafsson, and L. Haldosén, “Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity,” Breast Cancer Research, vol. 13, no. 2, article R43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Hurtado, K. A. Holmes, T. R. Geistlinger et al., “Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen,” Nature, vol. 456, no. 7222, pp. 663–666, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. D. Beauchemin, C. Lacombe, and C. van Themsche, “PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype,” Molecular Cancer, vol. 10, article 148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  150. T. Zuo, L. Wang, C. Morrison et al., “FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene,” Cell, vol. 129, no. 7, pp. 1275–1286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  151. G. Hua, B. Zhu, F. Rosa et al., “A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells,” Molecular Cancer Research, vol. 7, no. 3, pp. 402–414, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. M. Whitman, C. P. Downes, M. Keeler, T. Keller, and L. Cantley, “Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate,” Nature, vol. 332, no. 6165, pp. 644–646, 1988. View at Publisher · View at Google Scholar · View at Scopus
  153. K. E. Anderson, J. Coadwell, L. R. Stephens, and P. T. Hawkins, “Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B,” Current Biology, vol. 8, no. 12, pp. 684–691, 1998. View at Publisher · View at Google Scholar · View at Scopus
  154. T. F. Franke, S. I. Yang, T. O. Chan et al., “The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase,” Cell, vol. 81, no. 5, pp. 727–736, 1995. View at Publisher · View at Google Scholar · View at Scopus
  155. T. Maehama and J. E. Dixon, “The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate,” The Journal of Biological Chemistry, vol. 273, no. 22, pp. 13375–13378, 1998. View at Publisher · View at Google Scholar · View at Scopus
  156. C. Gewinner, Z. C. Wang, A. Richardson et al., “Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling,” Cancer Cell, vol. 16, no. 2, pp. 115–125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  157. R. A. Campbell, P. Bhat-Nakshatri, N. M. Patel, D. Constantinidou, S. Ali, and H. Nakshatri, “Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance,” The Journal of Biological Chemistry, vol. 276, no. 13, pp. 9817–9824, 2001. View at Publisher · View at Google Scholar · View at Scopus
  158. R. L. Yamnik, A. Digilova, D. C. Davis, Z. N. Brodt, C. J. Murphy, and M. K. Holz, “S6 kinase 1 regulates estrogen receptor α in control of breast cancer cell proliferation,” The Journal of Biological Chemistry, vol. 284, no. 10, pp. 6361–6369, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. O. A. Coso, M. Chiarielio, J.-C. Yu et al., “The small GTP-binding proteins rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway,” Cell, vol. 81, no. 7, pp. 1137–1146, 1995. View at Publisher · View at Google Scholar · View at Scopus
  160. A. Minden, A. Lin, F. Claret, A. Abo, and M. Karin, “Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPses Rac and Cdc42Hs,” Cell, vol. 81, no. 7, pp. 1147–1157, 1995. View at Publisher · View at Google Scholar · View at Scopus
  161. L. N. Petz, Y. S. Ziegler, M. A. Loven, and A. M. Nardulli, “Estrogen receptor α and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells,” Endocrinology, vol. 143, no. 12, pp. 4583–4591, 2002. View at Publisher · View at Google Scholar · View at Scopus
  162. T. W. Miller, M. Pérez-Torres, A. Narasanna et al., “Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer,” Cancer Research, vol. 69, no. 10, pp. 4192–4201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. T. W. Miller, J. M. Balko, and C. L. Arteaga, “Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer,” Journal of Clinical Oncology, vol. 29, no. 33, pp. 4452–4461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. R. R. Saleh, N. Bouganim, J. Hilton, A. Arnaout, and M. Clemons, “Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again?” Current Oncology, vol. 21, no. 1, pp. e122–e128, 2014. View at Publisher · View at Google Scholar
  165. C. W. Yde, K. B. Emdal, B. Guerra, and A. E. Lykkesfeldt, “NFκB signaling is important for growth of antiestrogen resistant breast cancer cells,” Breast Cancer Research and Treatment, vol. 135, no. 1, pp. 67–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  166. H. Shen and V. Tergaonkar, “NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy,” Apoptosis, vol. 14, no. 4, pp. 348–363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  167. L. V. Madrid, M. W. Mayo, J. Y. Reuther, and A. S. Baldwin Jr., “Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-κ B through utilization of the Iκ B kinase and activation of the mitogen-activated protein kinase p38,” The Journal of Biological Chemistry, vol. 276, no. 22, pp. 18934–18940, 2001. View at Publisher · View at Google Scholar · View at Scopus
  168. J. Frasor, A. Weaver, M. Pradhan et al., “Positive cross-talk between estrogen receptor and NF-κB in breast cancer,” Cancer Research, vol. 69, no. 23, pp. 8918–8925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  169. R. Nehra, R. B. Riggins, A. N. Shajahan, A. Zwart, A. C. Crawford, and R. Clarke, “BCL2 and CASP8 regulation by NF-κB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells,” FASEB Journal, vol. 24, no. 6, pp. 2040–2055, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. Y. Zhu, B. Singh, S. Hewitt et al., “Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays,” International Journal of Oncology, vol. 28, no. 1, pp. 67–76, 2006. View at Google Scholar · View at Scopus
  171. Z. Gu, R. Y. Lee, T. C. Skaar et al., “Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780),” Cancer Research, vol. 62, no. 12, pp. 3428–3437, 2002. View at Google Scholar · View at Scopus
  172. Y. Zhou, C. Yau, J. W. Gray et al., “Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer,” BMC Cancer, vol. 7, article 59, 2007. View at Publisher · View at Google Scholar · View at Scopus
  173. L. A. deGraffenried, B. Chandrasekar, W. E. Friedrichs et al., “NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen,” Annals of Oncology, vol. 15, no. 6, pp. 885–890, 2004. View at Publisher · View at Google Scholar · View at Scopus
  174. Y. Zhou, S. Eppenberger-Castori, U. Eppenberger, and C. C. Benz, “The NFκB pathway and endocrine-resistant breast cancer,” Endocrine-Related Cancer, vol. 12, supplement 1, pp. S37–S46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  175. G. Morrison, X. Fu, M. Shea et al., “Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance,” Breast Cancer Research and Treatment, vol. 144, no. 2, pp. 263–272, 2014. View at Publisher · View at Google Scholar
  176. M. Pradhan, L. A. Bembinster, S. C. Baumgarten, and J. Frasor, “Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NFκB cooperativity at adjacent response elements,” Journal of Biological Chemistry, vol. 285, no. 41, pp. 31100–31106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. K. W. Nettles, G. Gil, J. Nowak, R. Métivier, V. B. Sharma, and G. L. Greene, “CBP is a dosage-dependent regulator of nuclear factor-κB suppression by the estrogen receptor,” Molecular Endocrinology, vol. 22, no. 2, pp. 263–272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  178. S. Cutrupi, S. Reineri, A. Panetto et al., “Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells,” Oncogene, vol. 31, no. 40, pp. 4353–4361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  179. G. Takaesu, S. Kishida, A. Hiyama et al., “TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway,” Molecular Cell, vol. 5, no. 4, pp. 649–658, 2000. View at Publisher · View at Google Scholar · View at Scopus
  180. P. Viatour, M. Merville, V. Bours, and A. Chariot, “Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation,” Trends in Biochemical Sciences, vol. 30, no. 1, pp. 43–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  181. H. Bruunsgaard, M. Pedersen, and B. K. Pedersen, “Aging and proinflammatory cytokines,” Current Opinion in Hematology, vol. 8, no. 3, pp. 131–136, 2001. View at Publisher · View at Google Scholar · View at Scopus
  182. J. Pfeilschifter, R. Köditz, M. Pfohl, and H. Schatz, “Changes in proinflammatory cytokine activity after menopause,” Endocrine Reviews, vol. 23, no. 1, pp. 90–119, 2002. View at Publisher · View at Google Scholar · View at Scopus
  183. S. C. Baumgarten and J. Frasor, “Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers,” Molecular Endocrinology, vol. 26, no. 3, pp. 360–371, 2012. View at Publisher · View at Google Scholar · View at Scopus
  184. P. M. A. Kelly, R. S. Davison, E. Bliss, and J. McGee, “Macrophages in human breast disease: a quantitative immunohistochemical study,” British Journal of Cancer, vol. 57, no. 2, pp. 174–177, 1988. View at Publisher · View at Google Scholar · View at Scopus
  185. R. D. Leek, C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, and A. L. Harris, “Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma,” Cancer Research, vol. 56, no. 20, pp. 4625–4629, 1996. View at Google Scholar · View at Scopus
  186. T. Hagemann, J. Wilson, H. Kulbe et al., “Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK,” The Journal of Immunology, vol. 175, no. 2, pp. 1197–1205, 2005. View at Publisher · View at Google Scholar · View at Scopus
  187. S. Paik, S. Shak, G. Tang et al., “A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer,” New England Journal of Medicine, vol. 351, no. 27, pp. 2817–2826, 2004. View at Publisher · View at Google Scholar · View at Scopus
  188. S. Sheen-Chen, W. Chen, H. Eng, and F. Chou, “Serum concentration of tumor necrosis factor in patients with breast cancer,” Breast Cancer Research and Treatment, vol. 43, no. 3, pp. 211–215, 1997. View at Publisher · View at Google Scholar · View at Scopus
  189. D. W. Miles, L. C. Happerfield, M. S. Naylor, L. G. Bobrow, R. D. Rubens, and F. R. Balkwill, “Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissue,” International Journal of Cancer, vol. 56, no. 6, pp. 777–782, 1994. View at Publisher · View at Google Scholar · View at Scopus
  190. M. A. Rivas, R. P. Carnevale, C. J. Proietti et al., “TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways,” Experimental Cell Research, vol. 314, no. 3, pp. 509–529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  191. M. F. Rubio, S. Werbajh, E. G. A. Cafferata et al., “TNF-α enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B,” Oncogene, vol. 25, no. 9, pp. 1367–1377, 2006. View at Publisher · View at Google Scholar · View at Scopus
  192. H. Buss, A. Dörrie, M. L. Schmitz, E. Hoffmann, K. Resch, and M. Kracht, “Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-α, IKKβ, IKKϵ, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription,” The Journal of Biological Chemistry, vol. 279, no. 53, pp. 55633–55643, 2004. View at Publisher · View at Google Scholar · View at Scopus
  193. Y. Song, K. Jen, V. Soni, E. Kieff, and E. Cahir-McFarland, “IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-κB activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 8, pp. 2689–2694, 2006. View at Publisher · View at Google Scholar · View at Scopus
  194. D. B. Hardy, B. A. Janowski, C. Chen, and C. R. Mendelson, “Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-lndependent mechanisms,” Molecular Endocrinology, vol. 22, no. 8, pp. 1812–1824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  195. S. Kobayashi, J. P. Stice, D. Kazmin et al., “Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer,” Molecular Endocrinology, vol. 24, no. 12, pp. 2292–2302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  196. C. S. O'Brien, G. Farnie, S. J. Howell, and R. B. Clarke, “Breast cancer stem cells and their role in resistance to endocrine therapy,” Hormones and Cancer, vol. 2, no. 2, pp. 91–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  197. G. Farnie, R. B. Clarke, K. Spence et al., “Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways,” Journal of the National Cancer Institute, vol. 99, no. 8, pp. 616–627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  198. S. Y. Park, H. E. Lee, H. Li, M. Shipitsin, R. Gelman, and K. Polyak, “Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer,” Clinical Cancer Research, vol. 16, no. 3, pp. 876–887, 2010. View at Publisher · View at Google Scholar · View at Scopus
  199. S. Pece, D. Tosoni, S. Confalonieri et al., “Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content,” Cell, vol. 140, no. 1, pp. 62–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  200. C. Sheridan, H. Kishimoto, R. K. Fuchs et al., “CD44+/CD24Breast cancer cells exhibit enhanced invase properties: an early step necessary for metastasis,” Breast Cancer Research, vol. 8, no. 5, p. R59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  201. A. Ouhtit, Z. Y. Abd Elmageed, M. E. Abdraboh, T. F. Lioe, and M. H. G. Raj, “In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver,” The American Journal of Pathology, vol. 171, no. 6, pp. 2033–2039, 2007. View at Publisher · View at Google Scholar · View at Scopus
  202. C. J. Creighton, X. Li, M. Landis et al., “Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 13820–13825, 2009. View at Publisher · View at Google Scholar · View at Scopus
  203. C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar · View at Scopus
  204. M. Piva, M. Rábano, B. M. Simões et al., “Sox2 promotes tamoxifen resistance in breast cancer cells,” EMBO Molecular Medicine, vol. 6, no. 1, pp. 66–79, 2014. View at Google Scholar
  205. M. J. Sikora, V. Strumba, M. E. Lippman, M. D. Johnson, and J. M. Rae, “Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation,” Breast Cancer Research and Treatment, vol. 134, no. 3, pp. 1027–1039, 2012. View at Publisher · View at Google Scholar · View at Scopus
  206. C. M. W. Chan, L. Martin, S. R. D. Johnston, S. Ali, and M. Dowsett, “Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 81, no. 4-5, pp. 333–341, 2002. View at Publisher · View at Google Scholar · View at Scopus
  207. L. A. Martin, I. Farmer, S. R. D. Johnston, S. Ali, C. Marshall, and M. Dowsett, “Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation,” The Journal of Biological Chemistry, vol. 278, no. 33, pp. 30458–30468, 2003. View at Publisher · View at Google Scholar · View at Scopus
  208. M. H. Herynk, T. Hopp, Y. Cui, A. Niu, A. Corona-Rodriguez, and S. A. W. Fuqua, “A hypersensitive estrogen receptor α mutation that alters dynamic protein interactions,” Breast Cancer Research and Treatment, vol. 122, no. 2, pp. 381–393, 2010. View at Publisher · View at Google Scholar · View at Scopus
  209. J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-mesenchymal transitions in development and disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009. View at Publisher · View at Google Scholar · View at Scopus
  210. A. Voulgari and A. Pintzas, “Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic,” Biochimica et Biophysica Acta: Reviews on Cancer, vol. 1796, no. 2, pp. 75–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  211. I. R. G. Beavon, “The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation,” European Journal of Cancer, vol. 36, no. 13, pp. 1607–1620, 2000. View at Publisher · View at Google Scholar · View at Scopus
  212. C. Faleiro-Rodrigues, I. Macedo-Pinto, D. Pereira, V. M. Ferreira, and C. S. Lopes, “Association of E-cadherin and β-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas,” Human Pathology, vol. 35, no. 6, pp. 663–669, 2004. View at Publisher · View at Google Scholar · View at Scopus
  213. S. Hirohashi and Y. Kanai, “Cell adhesion system and human cancer morphogenesis,” Cancer Science, vol. 94, no. 7, pp. 575–581, 2003. View at Publisher · View at Google Scholar · View at Scopus
  214. A. Nagafuchi, “Molecular architecture of adherens junctions,” Current Opinion in Cell Biology, vol. 13, no. 5, pp. 600–603, 2001. View at Publisher · View at Google Scholar · View at Scopus
  215. S. Hiscox, W. G. Jiang, K. Obermeier et al., “Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation,” International Journal of Cancer, vol. 118, no. 2, pp. 290–301, 2006. View at Publisher · View at Google Scholar · View at Scopus
  216. A. Dhasarathy, M. Kajita, and P. A. Wade, “The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-α,” Molecular Endocrinology, vol. 21, no. 12, pp. 2907–2918, 2007. View at Publisher · View at Google Scholar · View at Scopus
  217. M. P. Trimarchi, M. Mouangsavanh, and T. H. Huang, “Cancer epigenetics: a perspective on the role of DNA methylatiion in acquired endocrine resistence,” Chinese Journal of Cancer, vol. 30, no. 11, pp. 749–756, 2011. View at Publisher · View at Google Scholar · View at Scopus
  218. M. Esteller, “Epigenetic changes in cancer,” F1000 Biology Reports, vol. 3, no. 1, article 9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  219. M. Hatziapostolou and D. Iliopoulos, “Epigenetic aberrations during oncogenesis,” Cellular and Molecular Life Sciences, vol. 68, no. 10, pp. 1681–1702, 2011. View at Publisher · View at Google Scholar · View at Scopus
  220. M. Szyf, “Epigenetics, DNA methylation, and chromatin modifying drugs,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 243–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  221. M. Fan, P. S. Yan, C. Hartman-Frey et al., “Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant,” Cancer Research, vol. 66, no. 24, pp. 11954–11966, 2006. View at Publisher · View at Google Scholar · View at Scopus
  222. T. van Agthoven, T. L. A. van Agthoven, A. Dekker, J. A. Foekens, and L. C. J. Dorssers, “Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations,” Molecular Endocrinology, vol. 8, no. 11, pp. 1474–1483, 1994. View at Publisher · View at Google Scholar · View at Scopus
  223. J. Martinez-Galan, B. Torres-Torres, M. Isabel Núñez et al., “ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients,” BMC Cancer, vol. 14, article 59, 2014. View at Publisher · View at Google Scholar
  224. H. G. Chang, S. J. Kim, K. Chung et al., “Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor β but not the estrogen receptor α gene,” Journal of Molecular Medicine, vol. 83, no. 2, pp. 132–139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  225. T. van Agthoven, A. M. Sieuwerts, J. Veldscholte et al., “CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer,” British Journal of Cancer, vol. 101, no. 11, pp. 1824–1832, 2009. View at Publisher · View at Google Scholar · View at Scopus
  226. I. Girault, I. Bièche, and R. Lidereau, “Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer,” Maturitas, vol. 54, no. 4, pp. 342–351, 2006. View at Publisher · View at Google Scholar · View at Scopus
  227. A. Stone, F. Valdés-Mora, J. M. W. Gee et al., “Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer,” PLoS ONE, vol. 7, no. 7, Article ID e40466, 2012. View at Publisher · View at Google Scholar · View at Scopus
  228. K. L. Cook, A. N. Shajahan, and R. Clarke, “Autophagy and endocrine resistance in breast cancer,” Expert Review of Anticancer Therapy, vol. 11, no. 8, pp. 1283–1294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  229. R. Clarke, “Cannibalism, cell survival, and endocrine resistance in breast cancer,” Breast Cancer Research, vol. 13, no. 4, article 311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  230. L. Gonzalez-Malerva, J. Park, L. Zou et al., “High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 5, pp. 2058–2063, 2011. View at Publisher · View at Google Scholar · View at Scopus
  231. J. M. Dixon, C. D. B. Love, L. Renshaw et al., “Lessons from the use of aromatase inhibitors in the neoadjuvant setting,” Endocrine-Related Cancer, vol. 6, no. 2, pp. 227–230, 1999. View at Publisher · View at Google Scholar · View at Scopus
  232. W. R. Miller, J. M. Dixon, L. Macfarlane, D. Cameron, and T. J. Anderson, “Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen,” European Journal of Cancer, vol. 39, no. 4, pp. 462–468, 2003. View at Publisher · View at Google Scholar · View at Scopus
  233. W. R. Miller, J. M. Dixon, D. A. Cameron, and T. J. Anderson, “Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy,” Journal of Steroid Biochemistry and Molecular Biology, vol. 79, no. 1–5, pp. 103–107, 2001. View at Publisher · View at Google Scholar · View at Scopus
  234. P. Robbins, S. Pinder, N. de Klerk et al., “Histological grading of breast carcinomas: a study of interobserver agreement,” Human Pathology, vol. 26, no. 8, pp. 873–879, 1995. View at Publisher · View at Google Scholar · View at Scopus
  235. W. R. Miller, “Aromatase inhibitors: prediction of response and nature of resistance,” Expert Opinion on Pharmacotherapy, vol. 11, no. 11, pp. 1873–1887, 2010. View at Publisher · View at Google Scholar · View at Scopus
  236. W. R. Miller, S. White, J. M. Dixon, J. Murray, L. Renshaw, and T. J. Anderson, “Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole,” British Journal of Cancer, vol. 94, no. 7, pp. 1051–1056, 2006. View at Publisher · View at Google Scholar · View at Scopus
  237. J. H. van Dierendonck, R. Keijzer, C. J. H. van de Velde, and C. J. Cornelisse, “Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells,” Cancer Research, vol. 49, no. 11, pp. 2999–3006, 1989. View at Google Scholar · View at Scopus
  238. J. Gerdes, H. Lemke, and H. Baisch, “Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67,” Journal of Immunology, vol. 133, no. 4, pp. 1710–1715, 1984. View at Google Scholar · View at Scopus
  239. S. du Manoir, P. Guillaud, E. Camus, D. Seigneurin, and G. Brugal, “Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment,” Cytometry, vol. 12, no. 5, pp. 455–463, 1991. View at Publisher · View at Google Scholar · View at Scopus
  240. T. Haerslev, G. K. Jacobsen, and K. Zedeler, “Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas,” Breast Cancer Research and Treatment, vol. 37, no. 2, pp. 101–113, 1996. View at Publisher · View at Google Scholar · View at Scopus
  241. M. A. Gonzalez, S. E. Pinder, G. Callagy et al., “Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4306–4313, 2003. View at Publisher · View at Google Scholar · View at Scopus
  242. I. F. Faneyte, J. G. Schrama, J. L. Peterse, P. L. Remijnse, S. Rodenhuis, and M. J. van de Vijver, “Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome,” The British Journal of Cancer, vol. 88, no. 3, pp. 406–412, 2003. View at Publisher · View at Google Scholar · View at Scopus
  243. T. Petit, M. Wilt, M. Velten et al., “Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy,” European Journal of Cancer, vol. 40, no. 2, pp. 205–211, 2004. View at Publisher · View at Google Scholar · View at Scopus
  244. C. L. Harper-Wynne, N. P. M. Sacks, K. Shenton et al., “Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer,” Journal of Clinical Oncology, vol. 20, no. 4, pp. 1026–1035, 2002. View at Publisher · View at Google Scholar · View at Scopus
  245. J. Chang, T. J. Powles, D. C. Allred et al., “Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients,” Clinical Cancer Research, vol. 6, no. 2, pp. 616–621, 2000. View at Google Scholar · View at Scopus
  246. A. Makris, T. J. Powles, D. C. Allred et al., “Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response,” Breast Cancer Research and Treatment, vol. 48, no. 1, pp. 11–20, 1998. View at Publisher · View at Google Scholar · View at Scopus
  247. Y. Tao, A. Klause, A. Vickers, K. Bae, and M. Ellis, “Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials,” Journal of Steroid Biochemistry and Molecular Biology, vol. 95, no. 1–5, pp. 91–95, 2005. View at Publisher · View at Google Scholar · View at Scopus
  248. M. J. Ellis, A. Coop, B. Singh et al., “Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial,” Journal of Clinical Oncology, vol. 19, no. 18, pp. 3808–3816, 2001. View at Google Scholar · View at Scopus
  249. R. M. Elledge, S. Green, R. Pugh et al., “Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study,” International Journal of Cancer, vol. 89, no. 2, pp. 111–117, 2000. View at Google Scholar
  250. P. M. Ravdin, S. Green, T. M. Dorr et al., “Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest oncology group study,” Journal of Clinical Oncology, vol. 10, no. 8, pp. 1284–1291, 1992. View at Google Scholar · View at Scopus
  251. M. M. Hefti, R. Hu, N. W. Knoblauch et al., “Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype,” Breast Cancer Research, vol. 15, article R68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  252. C. Wright, S. Nicholson, B. Angus et al., “Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer,” British Journal of Cancer, vol. 65, no. 1, pp. 118–121, 1992. View at Publisher · View at Google Scholar · View at Scopus
  253. P. Lal, L. K. Tan, and B. Chen, “Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas,” American Journal of Clinical Pathology, vol. 123, no. 4, pp. 541–546, 2005. View at Publisher · View at Google Scholar · View at Scopus
  254. X. J. Ma, R. Salunga, J. T. Tuggle et al., “Gene expression profiles of human breast cancer progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5974–5979, 2003. View at Google Scholar
  255. M. Dowsett, J. Houghton, C. Iden et al., “Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status,” Annals of Oncology, vol. 17, no. 5, pp. 818–826, 2006. View at Publisher · View at Google Scholar · View at Scopus
  256. B. Weigelt, F. L. Baehner, and J. S. Reis-Filho, “The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade,” Journal of Pathology, vol. 220, no. 2, pp. 263–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  257. A. H. Sims, K. R. Ong, R. B. Clarke, and A. Howell, “High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?” Breast Cancer Research, vol. 8, no. 5, p. 214, 2006. View at Publisher · View at Google Scholar · View at Scopus
  258. A. H. Sims, “Bioinformatics and breast cancer: what can high-throughput genomic approaches actually tell us?” Journal of Clinical Pathology, vol. 62, no. 10, pp. 879–885, 2009. View at Publisher · View at Google Scholar · View at Scopus
  259. L. J. Van't Veer, H. Dai, M. J. van de Vijver et al., “Gene expression profiling predicts clinical outcome of breast cancer,” Nature, vol. 415, no. 6871, pp. 530–536, 2002. View at Publisher · View at Google Scholar · View at Scopus
  260. J. A. Sparano and S. Paik, “Development of the 21-gene assay and its application in clinical practice and clinical trials,” Journal of Clinical Oncology, vol. 26, no. 5, pp. 721–728, 2008. View at Publisher · View at Google Scholar · View at Scopus
  261. M. Buyse, S. Loi, L. van't Veer et al., “Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer,” Journal of the National Cancer Institute, vol. 98, no. 17, pp. 1183–1192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  262. M. J. van de Vijver, Y. D. He, L. J. van 'T Veer et al., “A gene-expression signature as a predictor of survival in breast cancer,” The New England Journal of Medicine, vol. 347, no. 25, pp. 1999–2009, 2002. View at Publisher · View at Google Scholar · View at Scopus
  263. J. M. Bueno-de-Mesquita, W. H. van Harten, V. P. Retel et al., “Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER),” The Lancet Oncology, vol. 8, no. 12, pp. 1079–1087, 2007. View at Publisher · View at Google Scholar · View at Scopus
  264. M. J. van de Vijver, J. M. Bueno-de-Mesquita, S. C. Linn et al., “Validation of 70-gene prognosis signature in node-negative breast cancer,” Breast Cancer Research and Treatment, vol. 117, no. 3, pp. 483–495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  265. F. Cardoso, L. Van't Veer, E. Rutgers, S. Loi, S. Mook, and M. J. Piccart-Gebhart, “Clinical application of the 70-gene profile: the MINDACT trial,” Journal of Clinical Oncology, vol. 26, no. 5, pp. 729–735, 2008. View at Publisher · View at Google Scholar · View at Scopus
  266. M. E. Straver, A. M. Glas, J. Hannemann et al., “The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer,” Breast Cancer Research and Treatment, vol. 119, no. 3, pp. 551–558, 2010. View at Publisher · View at Google Scholar · View at Scopus
  267. R. Simon, “Development and validation of therapeutically relevant multi-gene biomarker classifiers,” Journal of the National Cancer Institute, vol. 97, no. 12, pp. 866–867, 2005. View at Publisher · View at Google Scholar · View at Scopus
  268. R. Simon, “Roadmap for developing and validating therapeutically relevant genomic classifiers,” Journal of Clinical Oncology, vol. 23, no. 29, pp. 7332–7341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  269. R. Simon, M. D. Radmacher, K. Dobbin, and L. M. McShane, “Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification,” Journal of the National Cancer Institute, vol. 95, no. 1, pp. 14–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  270. S. Paik, “Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen,” Oncologist, vol. 12, no. 6, pp. 631–635, 2007. View at Publisher · View at Google Scholar · View at Scopus
  271. L. J. Goldstein, R. Gray, S. Badve et al., “Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4063–4071, 2008. View at Publisher · View at Google Scholar · View at Scopus
  272. L. A. Habel, S. Shak, M. K. Jacobs et al., “A population-based study of tumor gene expression and risk of breast cancer death among lymp node-negative patients,” Breast Cancer Research, vol. 8, no. 3, p. R25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  273. S. Paik, G. Tang, S. Shak et al., “Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer,” Journal of Clinical Oncology, vol. 24, no. 23, pp. 3726–3734, 2006. View at Publisher · View at Google Scholar · View at Scopus
  274. L. Mina, S. E. Soule, S. Badve et al., “Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue,” Breast Cancer Research and Treatment, vol. 103, no. 2, pp. 197–208, 2007. View at Publisher · View at Google Scholar · View at Scopus
  275. C. Sotiriou, P. Wirapati, S. Loi et al., “Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis,” Journal of the National Cancer Institute, vol. 98, no. 4, pp. 262–272, 2006. View at Publisher · View at Google Scholar · View at Scopus
  276. S. Loi, B. Haibe-Kains, C. Desmedt et al., “Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade,” Journal of Clinical Oncology, vol. 25, no. 10, pp. 1239–1246, 2007. View at Google Scholar
  277. O. M. Filho, M. Ignatiadis, and C. Sotiriou, “Genomic Grade Index: an important tool for assessing breast cancer tumor grade and prognosis,” Critical Reviews in Oncology/Hematology, vol. 77, no. 1, pp. 20–29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  278. A. Tordai, J. Wang, F. Andre et al., “Evaluation of biological pathways involved in chemotherapy response in breast cancer,” Breast Cancer Research, vol. 10, no. 2, article R37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  279. J. Toussaint, A. M. Sieuwerts, B. Haibe-Kains et al., “Improvement of the clinical applicability of the genomic grade index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues,” BMC Genomics, vol. 10, article 424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  280. C. Desmedt, B. Haibe-Kains, P. Wirapati et al., “Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes,” Clinical Cancer Research, vol. 14, no. 16, pp. 5158–5165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  281. P. Wirapati, C. Sotiriou, S. Kunkel et al., “Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures,” Breast Cancer Research, vol. 10, no. 4, article R65, 2008. View at Publisher · View at Google Scholar · View at Scopus
  282. M. P. Goetz, V. J. Suman, J. N. Ingle et al., “A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen,” Clinical Cancer Research, vol. 12, no. 7, pp. 2080–2087, 2006. View at Publisher · View at Google Scholar · View at Scopus
  283. X. Ma, S. G. Hilsenbeck, W. Wang et al., “The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer,” Journal of Clinical Oncology, vol. 24, no. 28, pp. 4611–4619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  284. J. F. Reid, L. Lusa, L. De Cecco et al., “Limits of predictive models using microarray data for breast cancer clinical treatment outcome,” Journal of the National Cancer Institute, vol. 97, no. 12, pp. 927–930, 2005. View at Publisher · View at Google Scholar · View at Scopus
  285. W. F. Symmans, C. Hatzis, C. Sotiriou et al., “Genomic index of sensitivity to endocrine therapy for breast cancer,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4111–4119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  286. P. Dubsky, M. Filipits, R. Jakesz et al., “Endopredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer,” Annals of Oncology, vol. 24, no. 3, pp. 640–647, 2013. View at Publisher · View at Google Scholar · View at Scopus
  287. R. Kronenwett, K. Bohmann, J. Prinzler et al., “Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test,” BMC Cancer, vol. 12, article 456, 2012. View at Publisher · View at Google Scholar · View at Scopus
  288. M. Filipits, M. Rudas, R. Jakesz et al., “A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors,” Clinical Cancer Research, vol. 17, no. 18, pp. 6012–6020, 2011. View at Publisher · View at Google Scholar · View at Scopus
  289. C. Denkert, S. Loibl, A. Noske et al., “Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 105–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  290. L. D. Miller, J. Smeds, J. George et al., “An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13550–13555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  291. K. Holm, J. Staaf, G. Jönsson et al., “Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours,” Breast Cancer Research and Treatment, vol. 133, no. 2, pp. 583–594, 2012. View at Publisher · View at Google Scholar · View at Scopus
  292. S. Loi, B. Haibe-Kains, S. Majjaj et al., “PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 22, pp. 10208–10213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  293. C. J. Creighton, A. M. Hilger, S. Murthy, J. M. Rae, A. M. Chinnaiyan, and D. El-Ashry, “Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors,” Cancer Research, vol. 66, no. 7, pp. 3903–3911, 2006. View at Publisher · View at Google Scholar · View at Scopus
  294. R. Liu, X. Wang, G. Y. Chen et al., “The prognostic role of a gene signature from tumorigenic breast-cancer cells,” The New England Journal of Medicine, vol. 356, no. 3, pp. 217–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  295. S. A. Amundson, K. T. Do, L. C. Vinikoor et al., “Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen,” Cancer Research, vol. 68, no. 2, pp. 415–424, 2008. View at Google Scholar
  296. J. S. Reis-Filho, C. Westbury, and J.-Y. Pierga, “The impact of expression profiling on prognostic and predictive testing in breast cancer,” Journal of Clinical Pathology, vol. 59, no. 3, pp. 225–231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  297. A. A. Ahmed and J. D. Brenton, “Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt,” Breast Cancer Research, vol. 7, no. 3, pp. 96–99, 2005. View at Publisher · View at Google Scholar · View at Scopus
  298. J. D. Brenton, L. A. Carey, A. Ahmed, and C. Caldas, “Molecular classification and molecular forecasting of breast cancer: ready for clinical application?” Journal of Clinical Oncology, vol. 23, no. 29, pp. 7350–7360, 2005. View at Publisher · View at Google Scholar · View at Scopus
  299. M. Thomassen, Q. Tan, F. Eiriksdottir, M. Bak, S. Cold, and T. A. Kruse, “Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer,” Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5355–5360, 2007. View at Publisher · View at Google Scholar · View at Scopus
  300. B. Haibe-Kains, C. Desmedt, F. Piette et al., “Comparison of prognostic gene expression signatures for breast cancer,” BMC Genomics, vol. 9, article 394, 2008. View at Publisher · View at Google Scholar · View at Scopus
  301. B. Haibe-Kains, C. Desmedt, C. Sotiriou, and G. Bontempi, “A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?” Bioinformatics, vol. 24, no. 19, pp. 2200–2208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  302. C. Fan, D. S. Oh, L. Wessels et al., “Concordance among gene-expression-based predictors for breast cancer,” New England Journal of Medicine, vol. 355, no. 6, pp. 560–569, 2006. View at Publisher · View at Google Scholar · View at Scopus
  303. R. Natrajan, M. B. K. Lambros, F. C. Geyer et al., “Loss of I6q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?” Genes Chromosomes and Cancer, vol. 48, no. 4, pp. 351–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  304. R. Natrajan, M. B. Lambros, S. Maríarodríguez-Pinilla et al., “Tiling path genomic profiling of grade 3 invasive ductal breast cancers,” Clinical Cancer Research, vol. 15, no. 8, pp. 2711–2722, 2009. View at Publisher · View at Google Scholar · View at Scopus
  305. F. Reyal, M. H. van Vliet, N. J. Armstrong et al., “A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer,” Breast Cancer Research, vol. 10, no. 6, article R93, 2008. View at Publisher · View at Google Scholar · View at Scopus
  306. A. E. Teschendorff and C. Caldas, “A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer,” Breast Cancer Research, vol. 10, no. 4, article R73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  307. A. E. Teschendorff, A. Miremadi, S. E. Pinder, I. O. Ellis, and C. Caldas, “An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer,” Genome Biology, vol. 8, article R157, no. 8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  308. M. P. H. M. Jansen, J. A. Foekens, I. L. Van Staveren et al., “Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 732–740, 2005. View at Publisher · View at Google Scholar · View at Scopus
  309. A. Mackay, A. Urruticoechea, J. M. Michael et al., “Molecular response to aromatase inhibitor treatment in primary breast cancer,” Breast Cancer Research, vol. 9, no. 3, p. R37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  310. D. M. E. Harvell, J. K. Richer, M. Singh et al., “Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 489–501, 2008. View at Publisher · View at Google Scholar · View at Scopus
  311. D. M. E. Harvell, N. S. Spoelstra, M. Singh et al., “Molecular signatures of neoadjuvant endocrine therapy for breast cancer: Characteristics of response or intrinsic resistance,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 475–488, 2008. View at Publisher · View at Google Scholar · View at Scopus
  312. A. H. Sims, G. J. Smethurst, Y. Hey et al., “The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets—improving meta-analysis and prediction of prognosis,” BMC Medical Genomics, vol. 1, article 42, 2008. View at Google Scholar
  313. R. R. Kitchen, V. S. Sabine, A. H. Sims et al., “Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles,” BMC Genomics, vol. 11, no. 1, article 134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  314. W. R. Miller and A. Larionov, “Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole,” Breast Cancer Research, vol. 12, no. 4, article R52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  315. B. J. Long, D. Jelovac, V. Handratta et al., “Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model,” Journal of the National Cancer Institute, vol. 96, no. 6, pp. 456–465, 2004. View at Publisher · View at Google Scholar · View at Scopus
  316. M. Dowsett, C. Pfister, S. R. D. Johnston et al., “Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer,” Clinical Cancer Research, vol. 5, no. 9, pp. 2338–2343, 1999. View at Google Scholar · View at Scopus
  317. D. Jelovac, L. Macedo, O. G. Goloubeva, V. Handratta, and A. M. H. Brodie, “Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model,” Cancer Research, vol. 65, no. 12, pp. 5439–5444, 2005. View at Publisher · View at Google Scholar · View at Scopus
  318. R. S. Mehta, W. E. Barlow, K. S. Albain et al., “Combination anastrozole and fulvestrant in metastatic breast cancer,” New England Journal of Medicine, vol. 367, no. 5, pp. 435–444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  319. J. Bergh, P. Jönsson, E. K. Lidbrink et al., “FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1919–1925, 2012. View at Publisher · View at Google Scholar · View at Scopus
  320. A. Di Leo, G. Jerusalem, L. Petruzelka et al., “Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer,” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4594–4600, 2010. View at Publisher · View at Google Scholar
  321. P. Fedele, N. Calvani, A. Marino et al., “Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?” Critical Reviews in Oncology/Hematology, vol. 84, no. 2, pp. 243–251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  322. R. Nahta and R. M. O'Regan, “Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers,” Breast Cancer Research and Treatment, vol. 135, no. 1, pp. 39–48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  323. A. Barnadas, L. G. Estévez, A. Lluch-Hernández, A. Rodriguez-Lescure, C. Rodriguez-Sanchez, and P. Sanchez-Rovira, “An overview of letrozole in postmenopausal women with hormone-responsive breast cancer,” Advances in Therapy, vol. 28, no. 12, pp. 1045–1058, 2011. View at Publisher · View at Google Scholar · View at Scopus
  324. C. M. Barnett, “Everolimus: targeted therapy on the horizon for the treatment of breast cancer,” Pharmacotherapy, vol. 32, no. 4, pp. 383–396, 2012. View at Publisher · View at Google Scholar · View at Scopus
  325. A. Cavazzoni, M. A. Bonelli, C. Fumarola et al., “Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones,” Cancer Letters, vol. 323, no. 1, pp. 77–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  326. C. Villarreal-garza, J. Cortes, F. Andre, and S. Verma, “mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions,” Annals of Oncology, vol. 23, no. 10, Article ID mds075, pp. 2526–2535, 2012. View at Publisher · View at Google Scholar · View at Scopus
  327. S. R. D. Johnston, “BOLERO-2—will this change practice in advanced breast cancer?” Breast Cancer Research, vol. 14, no. 3, article 311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  328. J. Baselga, M. Campone, M. Piccart et al., “Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer,” The New England Journal of Medicine, vol. 366, no. 6, pp. 520–529, 2012. View at Publisher · View at Google Scholar · View at Scopus
  329. M. Gnant, R. Greil, M. Hubalek, and G. Steger, “Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an Austrian expert panel discussion,” Breast Care, vol. 8, no. 4, pp. 293–299, 2013. View at Publisher · View at Google Scholar
  330. S. Massarweh, E. Romond, E. P. Black et al., “A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure,” Breast Cancer Research and Treatment, vol. 143, no. 2, pp. 325–332, 2014. View at Publisher · View at Google Scholar
  331. G. C. Bobustuc, J. S. Smith, S. Maddipatla et al., “MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy,” Molecular Medicine, vol. 18, no. 6, pp. 913–929, 2012. View at Publisher · View at Google Scholar · View at Scopus
  332. A. Agrawal, J. F. R. Robertson, and K. L. Cheung, “Clinical relevance of “withdrawal therapy” as a form of hormonal manipulation for breast cancer,” World Journal of Surgical Oncology, vol. 9, article 101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  333. G. Sabnis, O. Goloubeva, R. Gilani, L. Macedo, and A. Brodie, “Sensitivity to the aromatase inhibitor letrozole is prolonged after a “break” in treatment,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 46–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  334. J. S. Lewis-Wambi and V. C. Jordan, “Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?” Breast Cancer Research, vol. 11, no. 3, article 206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  335. E. A. Ariazi, H. E. Cunliffe, J. S. Lewis-Wambi et al., “Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 47, pp. 18879–18886, 2011. View at Publisher · View at Google Scholar · View at Scopus